Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Cut to $17.00 by Analysts at Needham & Company LLC

Verrica Pharmaceuticals (NASDAQ:VRCA) had its target price cut by Needham & Company LLC from $20.00 to $17.00 in a research report report published on Tuesday morning, BenzingaRatingsTable reports. They currently have a buy rating on the stock.

A number of other equities analysts have also recently issued reports on VRCA. ValuEngine upgraded Verrica Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, March 17th. Northland Securities assumed coverage on Verrica Pharmaceuticals in a report on Wednesday, June 24th. They issued an outperform rating and a $21.00 target price for the company. Zacks Investment Research cut Verrica Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, June 25th. HC Wainwright reiterated a buy rating and issued a $24.00 target price on shares of Verrica Pharmaceuticals in a report on Monday, May 18th. Finally, BidaskClub upgraded Verrica Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, June 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $16.75.

NASDAQ VRCA opened at $14.07 on Tuesday. The company has a market cap of $366.31 million, a P/E ratio of -11.53 and a beta of 2.39. The company has a debt-to-equity ratio of 0.61, a quick ratio of 27.45 and a current ratio of 27.45. The business’s 50 day moving average price is $12.05 and its 200-day moving average price is $12.74. Verrica Pharmaceuticals has a fifty-two week low of $6.79 and a fifty-two week high of $18.67.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.01). As a group, equities analysts predict that Verrica Pharmaceuticals will post -2.32 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRCA. Kornitzer Capital Management Inc. KS raised its position in shares of Verrica Pharmaceuticals by 5.8% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 470,274 shares of the company’s stock worth $5,140,000 after acquiring an additional 25,743 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Verrica Pharmaceuticals by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 163,235 shares of the company’s stock worth $2,593,000 after acquiring an additional 19,510 shares in the last quarter. State Street Corp raised its position in shares of Verrica Pharmaceuticals by 7.7% in the 4th quarter. State Street Corp now owns 224,524 shares of the company’s stock worth $3,568,000 after acquiring an additional 16,098 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Verrica Pharmaceuticals in the 1st quarter worth $167,000. Finally, Renaissance Technologies LLC bought a new position in shares of Verrica Pharmaceuticals in the 4th quarter worth $221,000. 34.45% of the stock is owned by hedge funds and other institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Featured Article: Accumulation/Distribution

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.